BioCentury
ARTICLE | Strategy

Trans-Atlantic play

March 5, 2007 8:00 AM UTC

Backed by a $175 million infusion from investors, EUSA Pharma Inc. says last week's acquisition of specialty pharma company OPi S.A. will provide revenues, products and infrastructure that will serve as the European foundation for becoming a trans-Atlantic specialty pharma company with equally important U.S. and EU operations.

OPi (Lyon, France) was a good strategic fit for three primary reasons, according to Bryan Morton, president, CEO and founder of EUSA (King of Prussia, Penn.). "First, they have good products with rights in the EU and U.S.; second, they have good corporate structure that provides things like a supply chain, medical affairs and pharmacovigilance; and, third, they already had sales revenues." ...